Does Ozempic Cause Muscle Loss? What the Research Actually Says

When semaglutide users step on the scale and watch the numbers fall, most assume they’re losing fat. The reality is more complicated — and for men who care about staying strong, it’s worth understanding. A 2024 narrative review published in Diabetes Care found that GLP-1 receptor agonists like semaglutide cause rapid and significant loss of lean mass — roughly 10% of total body weight lost, or approximately 6 kilograms of muscle — an amount the authors described as comparable to a decade or more of biological aging. That’s not a rounding error. That’s a meaningful physiological cost that deserves serious attention.

This doesn’t mean semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) is a bad drug. The cardiovascular benefits, glycemic improvements, and fat loss it produces are well-documented. But the question of what happens to your muscle while you’re losing weight on it is one that too few patients — and frankly, too few clinicians — are asking loudly enough.

What the Evidence Shows About Semaglutide and Muscle

The muscle loss concern isn’t theoretical. A 24-month retrospective cohort study published in 2025 in Drug Design, Development and Therapy tracked 220 older adults with type 2 diabetes on semaglutide and compared them to a matched control group. Researchers measured appendicular skeletal muscle mass index, grip strength, and gait speed over two years. The findings were sobering: semaglutide significantly reduced muscle mass compared to controls, and higher doses were associated with greater losses. In men, grip strength showed an initial improvement before declining — a pattern that suggests the medication may temporarily mask functional decline before the structural losses catch up. Gait speed dropped in both sexes. The study’s authors concluded that muscle loss and functional decline are real risks, particularly at higher doses and in patients who already have compromised muscle — a condition known as sarcopenia.

That last point matters more than most people realize. A 2025 review in Diabetes focused specifically on sarcopenic obesity — the combination of excess body fat and reduced muscle mass — and raised pointed concerns about using GLP-1 receptor agonists in older adults with this condition. The authors noted that while these medications show clear promise in younger populations, they have not been exhaustively studied in older adults, and the risk of accelerating muscle loss in people who can least afford it remains underappreciated. Sarcopenic obesity already affects an estimated 28.3% of adults over 60, and interventions that strip away lean tissue in this group carry real downstream risks for mobility, independence, and mortality.

Why does this happen? The primary mechanism isn’t some exotic pharmacology — it’s caloric restriction. When you eat significantly less, your body loses both fat and lean tissue. GLP-1 receptor agonists reduce appetite dramatically, which drives a large caloric deficit, which produces weight loss that is compositionally similar to aggressive dieting: roughly 25 to 40 percent of the weight lost tends to come from lean mass rather than fat. The drug isn’t targeting your muscle directly, but the profound appetite suppression it creates sets the physiological stage for it.

The Bigger Picture: Benefits, Tradeoffs, and What This Means Practically

It’s important not to read this evidence in isolation. A sweeping 2026 review in The Lancet Diabetes & Endocrinology synthesized data from randomized controlled trials and meta-analyses on GLP-1-based therapies and found beneficial effects across a remarkable range of conditions — type 2 diabetes, cardiovascular disease, metabolic dysfunction-associated steatotic liver disease, obstructive sleep apnea, and more. The authors noted that many of these benefits are mediated by weight loss itself, but that GLP-1 receptor agonists also appear to have meaningful weight-loss-independent effects, particularly on inflammation and organ function. On the question of muscle mass specifically, the review acknowledged it as a real concern that needs to be addressed in clinical practice.

There’s also intriguing mechanistic research suggesting semaglutide has protective effects on tissues beyond fat cells. A 2024 study in Nature Communications demonstrated that semaglutide improved cardiac function in male mice with heart failure by optimizing energy substrate utilization — preserving mitochondrial structure and promoting fatty acid oxidation through a pathway involving the Creb5/NR4a1 axis. While this doesn’t directly address skeletal muscle, it suggests the drug interacts with energy metabolism at a cellular level in ways researchers are still mapping. The full picture of what GLP-1 agonism does to the body beyond appetite suppression is still being written.

For men using semaglutide or considering it, the central practical question isn’t whether to take the medication — that’s a conversation for you and your physician. The question is what you do alongside it to protect the muscle you’ve built. And here, the research is encouragingly clear. The same Diabetes Care review that quantified the lean mass losses also found that supervised resistance training programs lasting more than 10 weeks produced average gains of approximately 3 kilograms of lean mass and strength improvements of around 25 percent. That’s not a trivial offset. If semaglutide costs you 6 kilograms of lean mass over the course of treatment, a structured resistance program can meaningfully blunt that loss — and potentially turn a net negative into something closer to a wash, or even a gain in muscle quality if fat is dropping simultaneously.

The practical implications extend beyond aesthetics. Muscle mass is metabolic currency. Men who lose significant lean tissue during a weight loss phase — whether through aggressive dieting, GLP-1 therapy, or both — are more vulnerable to weight regain when the intervention ends, because muscle drives resting metabolic rate. The Diabetes Care authors made exactly this point: retaining lean mass during incretin therapy could blunt fat regain when the medication is discontinued. The men who come off semaglutide and bounce back toward their original weight are often the ones who didn’t prioritize resistance training and protein intake during the treatment period.

Speaking of protein — this is where dietary strategy becomes non-negotiable regardless of what medication you’re on. When appetite is suppressed, the easiest calories to cut are often protein calories, because GLP-1 users frequently find they can satisfy their reduced hunger with smaller, carbohydrate-heavy meals. Deliberately prioritizing protein — aiming for at least 0.7 to 1 gram per pound of bodyweight daily — combined with two to four resistance training sessions per week represents the evidence-based foundation for muscle preservation during any weight loss phase, medicated or not. Leucine-rich protein sources — eggs, chicken, Greek yogurt, cottage cheese, whey — are particularly important because leucine is the primary amino acid trigger for muscle protein synthesis.

The Takeaway

Semaglutide does cause muscle loss, and the research is clear enough that this shouldn’t be hand-waved away by anyone prescribing or taking it. The losses are real, they’re clinically meaningful, and in older men or those already dealing with reduced muscle mass, they carry genuine health risks. At the same time, these losses are not inevitable at their maximum severity — they are modifiable by how you train and eat during treatment. If you’re on a GLP-1 medication, resistance training isn’t optional. It’s the counterweight the evidence demands. If you’re losing weight through diet and exercise alone, the same logic applies: protect your muscle aggressively, because the scale doesn’t distinguish between fat and lean tissue when you’re in a caloric deficit. The goal isn’t just a lower number — it’s a better body composition, and that requires intention, not just medication.